Vinmec performs its first total femoral replacement for world's youngest cancer patient
HANOI, VIETNAM - Media OutReach Newswire - 11 June 2025 - Vinmec Healthcare System has successfully performed a Total Femoral Replacement (TFR) surgery using personalized 3D printing materials for the world's youngest cancer patient. It is also the first biomedical product designed and produced entirely in Vietnam, marking a major milestone in the country's advancement in precision medicine.
Vinmec successfully performs world's youngest pediatric total femur replacement surgery using 3D printing technology.
Refusing to Surrender to Fate
In October 2022, after a minor fall, Tran Minh Duc (a boy from Ho Chi Minh City) hurt his left thigh. Believing it to be just a simple injury, his family was shocked to hear the bad news from the doctor: The boy was diagnosed with osteosarcoma - a malignant bone cancer with a tumor that had invaded his entire femur. It is typically seen in adolescents, but rare and haphazard in younger children.
Given the severe prognosis, most medical facilities recommended amputation to ensure his survival or bone grafting (a conventional method). Both methods carry a high risk of rejection and infection, especially for younger children in the development stage.
The flash of hope appeared when she met Prof. Dr. Tran Trung Dung - Director of the Orthopedic Council, Vinmec Healthcare System. An unprecedented approach was proposed to apply to such a young patient: replacing the entire femur with personalized 3D-printed materials that are produced in Vietnam.
A 'Legendary' Surgery with Vietnamese Technologies
According to Prof. Dr. Tran Trung Dung, the entire femur of Duc has been invaded by the tumor. To ensure his life, Duc's leg had to be amputated. However, different types of artificial joints available on the market are not compatible with young bodies.
After various interdisciplinary case conferences including Orthopedics, Oncology, Diagnostic Imaging, Pathology, Clinical Pharmacy, etc., the Vinmec experts reached a consensus on the optimal approach - a two-phase surgery. Phase 1 (January 2024): Removing the tumor and temporarily grafting a cement bone. Phase 2 (May 2025): Replacing the entire femur with a 'customized' bone made of 3D-printed metal.
On January 29, 2024, Duc underwent his first surgery - removing the entire tumor and temporarily grafting a cement bone. In May 2025 when his conditions had stabilized, Duc's entire femur was replaced with a 'customized' bone made of 3D-printed metal. For the first time, 3D printing was applied to the youngest patient in the world with the collaboration between Vinmec medical professionals and VinUni's engineers. The bone's design is modular, enabling future extensions based on the child's physical development.
According to MSc. Dr. Tran Duc Thanh, who was directly engaged in the surgery: 'We contacted foreign manufacturers but there was no suitable design. Self-manufacturing the equipment allows us to be proactive in treatment, it also paves the way for a new direction for Vietnamese medicine.'
Prof. Dr. Tran Trung Dung added: 'The 4-hour surgery was a success. Duc recovered quickly without any complications, now he is able to walk with the support of physical therapy. The surgery represented a breakthrough in complex techniques and the evidence for sound collaboration in the multidisciplinary medical team. Both the life and limb of the child were kept intact.'
Vinmec - Pioneering in Vietnam's Personalized Precision Medicine
Once at risk of amputation and life-long dependence, Minh Duc is now able to walk on his own feet, supported by physical therapy without any complications of infection or transplant rejection. Every step Duc takes is a testament to precision medicine, advanced technologies, and the unwavering love of his mother.
'When my son stood up, I was trembling with joy. He has been unable to walk for nearly two years. Now he did it. I just hope that he will be capable of riding a bike and playing football like his peers...' - Ms. Hoang said in tears.
Prof. Dr. Tran Trung Dung also shared his emotions: 'We believe that modern medicine and compassion should go side by side. Duc is not just a special patient, his case represents a story of determination, maternal love, and the faith that the impossible can become possible if we never give up.'
Vinmec is the first Vietnamese healthcare system that applies personalized 3D printing in the treatment of musculoskeletal conditions. Instead of using standardized equipment, Vinmec uses CT and MRI data in the design of artificial joints and bones tailored to each patient to optimize motor functions, enhance precision, and reduce the recovery period.
To date, Vinmec has achieved successes in many difficult and rare cases, e.g. liver transplantation for an 8-month-old patient from a brain-dead donor, the first in Southeast Asia to reproduce 3D-printed titanium chest wall, and the first in the world to replace the pelvis and femur at the same time with 3D-printed bones.
With its series of breakthroughs and pioneering achievements in high-tech healthcare and precision medicine, Vinmec further affirms the aspiration to elevate the position of Vietnam in the global medical field.
Vinmec - A Place of Healing and Reimagining the Future.
Hashtag: #Vinmec
https://www.vinmec.com/eng/
The issuer is solely responsible for the content of this announcement.
About Vinmec Healthcare System
Vinmec is Vietnam's leading private healthcare system, with a network of 9 hospitals nationwide, developed to international standards with a focus on comprehensive, personalized, and specialty care. Its proud achievements include:
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
EarlyHealth Group and UWI Launch Breakthrough Research Partnership to Tackle Caribbean Genetic Disorders
BRIDGETOWN, Barbados, June 20, 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group (EHG), a global pharmaceutical company, and The University of the West Indies (The UWI) have announced a landmark partnership to accelerate clinical research and biomarker innovation throughout Barbados and the wider Caribbean. This collaboration aims to accelerate advanced biobanking infrastructure and incorporate genotype-based biomarkers into regional clinical and translational research. The initiative will focus on identifying the genetic basis of hereditary disorders that disproportionately affect Caribbean populations, including hemoglobinopathies, oncogenic mutations, and metabolic syndromes. By leveraging the region's distinct genomic diversity and The UWI's strong research capacity, the partnership is poised to drive precision medicine approaches tailored to Caribbean communities. This will improve diagnostic accuracy, enhance therapeutic targeting, and lead to better health outcomes across the region. 'This collaboration represents an important step forward in The UWI's mission to elevate health research in the Caribbean,' said Dr. Damian Cohall, Dean of the Faculty of Medical Sciences. 'Through this partnership, EarlyHealth will not only support capacity-building efforts, such as laboratory enhancements and regulatory training, but help empower our scientific community to bring cutting-edge research closer to the people of the Caribbean, while contributing to the global scientific landscape.''We are excited to leverage our global sponsor network alongside The UWI's deep understanding of Caribbean health needs, to create new clinical research opportunities for the region,' said Mr. Shaquille Williams, Director of Business Development for the Caribbean Region. This strategic alliance underlines EHG's and The UWI's commitment to advancing evidence-based healthcare solutions for the Caribbean, while positioning the region as an emerging contributor to global pharmaceutical and biomedical innovation. This initiative, facilitated by the Embassy of Barbados in the United Arab Emirates, highlights the growing importance of commercial diplomacy in a fast-changing multi-polar world. About EarlyHealth Group EarlyHealth Group is a global pharmaceutical company specializing in research, clinical trial management, and commercialization, driven by a core mission to make healthcare accessible. Learn more at About The University of the West Indies The UWI has been central to Caribbean development for over 75 years. Today, it is an internationally respected institution with five campuses: Mona in Jamaica, St. Augustine in Trinidad and Tobago, Cave Hill in Barbados, Five Islands in Antigua and Barbuda and its Global Campus, with global centres in partnership with universities in North America, Latin America, Asia, Africa, and Europe. Learn more at A photo accompanying this announcement is available at CONTACT: For media inquiries, please contact: EarlyHealth Group Communications Email: press@ in to access your portfolio
Medscape
2 days ago
- Medscape
Fast Five Quiz: Cancer Diagnostics and Precision Medicine
Over the past decade, precision medicine has transformed cancer diagnostics and treatment by tailoring therapy to a patient's tumor biology based on molecular alterations rather than histologic subtypes or origins. Precision oncology often relies on molecular profiling through next-generation sequencing (NGS) to identify genomic events that can guide management. Techniques like targeted panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS) provide different analysis levels, chosen based on tumor type, tissue, and therapy relevance. How much do you know about cancer diagnostics and precision medicine? Test your knowledge with this quick quiz. WGS is an NGS method that analyzes the entire DNA sequence of an organism, including both coding and noncoding regions. WGS offers broad genomic coverage, detecting structural variants, intergenic mutations, and copy number changes often missed by targeted methods. Clinically, it has been useful in identifying ERBB2 ( HER2 ) amplifications in breast cancer or complex epidermal growth factor receptor ( EGFR ) alterations in lung cancer that might not be captured by smaller panels, helping guide targeted therapy. However, its lower sequencing depth (30-60×) typically limits the detection of low-frequency variants in heterogeneous tumors, such as a subclonal TP53 mutation affecting a small subset of cells and potentially impacting treatment response, which WGS may miss due to its lower depth. WES focuses only on the protein-coding regions, offering greater depth than WGS but limited breadth; however, it misses important regulatory and noncoding mutations. For example, TERT promoter mutations in glioblastoma are clinically relevant but lie outside the exome and would be missed by WES. Targeted panels are NGS tests that focus on specific disease-related genes and, until recently, were the predominant method used for comprehensive genomic profiling in clinical settings. They offer high depth for detecting low-frequency, actionable mutations but have limited coverage and might miss rare alterations outside the selected genes. Sanger sequencing is a method that reads DNA by generating fragments of varying lengths using chain-terminating nucleotides. It is accurate for small regions but has low throughput and cannot detect low-frequency mutations, making it unsuitable for large-scale cancer genomics. Unlike WGS, which surveys the entire genome, Sanger covers only targeted regions, so it does not offer broad genomic coverage and is therefore not the correct answer. Learn more about molecular profiling in oncology diagnostics. TS panels analyze specific genes relevant to oncology, and by focusing on a smaller subset of the genome (a few dozen to a few hundred genes), these panels require fewer sequencing data, resulting in faster turnaround times and simplified data interpretation compared with WGS or WES. This targeted approach enhances sensitivity for detecting clinically actionable somatic mutations, especially in small or heterogeneous tumor samples. For example, targeted NGS panels in non-small cell lung cancer (NSCLC) can rapidly detect EGFR mutations, ALK rearrangements, and other actionable alterations, allowing oncologists to initiate targeted therapies based on the mutation profile promptly. TS also demands less data storage and computational processing compared with WGS or WES, resulting in faster turnaround times and lower costs. These attributes make TS especially well-suited for clinical settings where accuracy, speed, and cost-effectiveness are paramount Learn more about clinical practice guidelines in the use of precision medicine in oncology. Tissue is generally preferred for initial genomic profiling because it contains a higher concentration of tumor DNA, allowing for more accurate detection of somatic mutations. This is especially important in early-stage cancers or tumors that do not shed much DNA into the bloodstream to be detectable by liquid biopsy. The tissue also allows for additional analyses like immunohistochemistry for PD-L1 or assessment of tumor histology to guide therapy. Further, immunohistochemistry plays an important role in precision medicine by identifying protein biomarkers to help determine the use of immune checkpoint inhibitors in NSCLC, triple-negative breast cancer, and urothelial carcinoma. Blood-based tests (ie, liquid biopsies) generally yield lower tumor DNA and do not inherently offer deeper sequencing but are generally more cost-effective than tissue biopsies. Regulatory agencies currently accept blood-based tests (eg, FDA-approved liquid biopsies), but they are typically used when tissue is unavailable or there is insufficient tissue. Learn more about tissue-based profiling Liquid biopsy, particularly through the analysis of circulating tumor DNA (ctDNA), has emerged as a valuable tool for monitoring MRD after treatment. By detecting small amounts of tumor-derived genetic material in the blood, liquid biopsy enables early identification of molecular relapse, often before clinical or radiographic evidence of recurrence is apparent. This makes it particularly useful in post-treatment surveillance of cancers such as colorectal, breast, and NSCLC. Diagnosing lymphomas typically requires tissue biopsy to assess architectural patterns and immunophenotyping; it is also commonly regarded as the standard for diagnosis. PD-L1 expression is a protein-based biomarker typically measured by immunohistochemistry on tissue samples, not usually through ctDNA. However, researchers have stated, 'ctDNA response is a potential biomarker for predicting the efficacy and prognosis of first-line PD-1 inhibitor therapy combined with chemotherapy' in patients with advanced gastric cancer. ctDNA also has been shown to predict responses in patients using PD-1/PD-L1 immune checkpoint inhibitors. Tumor staging usually relies on imaging modalities and pathologic evaluation rather than ctDNA analysis alone. Learn more about clinical practice guidelines in the use of precision medicine in oncology. A high TMB is considered useful because it is associated with abnormal proteins that make the tumor more recognizable to the immune system. TMB is measured using NGS by counting the number of somatic, nonsynonymous mutations per megabase of DNA; it is typically assessed using WES or large targeted panels. A TMB of 10 or more mutations per megabase is considered 'high,' based on data from the KEYNOTE-158 trial. This led to the FDA approval of an immune checkpoint inhibitor for TMB-high solid tumors, for example. High TMB is not usually linked to fewer side effects; side effect profiles tend to depend on the therapy, not mutation count. Low TMB has been shown to lead to fewer neoantigens and typically less immune visibility. Typically, TMB directly measures the number of mutations, not PD-L1 protein expression. Learn more about immunotherapy diagnostics.
Medscape
2 days ago
- Medscape
Global Laser Charities Save Skin and Change Lives
ORLANDO, Fla. — In 2009, Thanh-Nga Tran, MD, was a dermatology resident at Massachusetts General Hospital in Boston when she traveled to Vietnam — the country of her birth — for a clinical rotation. There, Tran found that children with vascular and pigmented birthmarks were being treated not with energy-based devices, as had long been standard in the US, or propranolol, which was emerging an effective treatment for hemangiomas at the time. Instead, they were treated with a topical paste containing phosphorus-32 (P-32), a radioactive isotope. The practice was introduced by French doctors there in the 1950s, and Vietnam's cancer hospitals had continued using it since that time. Images of children showing the results of treatment of vascular and pigmented birthmarks with radioactive phosphorus-32. Credit: Vietnam VAC The treatment with P-32 left children worse off than the lesions themselves in many cases, with severe scarring and depigmentation of the treated areas. R. Rox Anderson, MD When Tran returned to Boston, she consulted with her mentor, Dermatologist and Laser Medicine Pioneer R. Rox Anderson, MD, director of the Wellman Center for Photomedicine at Massachusetts General Hospital, Boston, about bringing pulsed-dye laser technology to Vietnam and training physicians in its use. 'I begged Rox to help me find a way to help treat these children,' Tran recalled. Top specialists, including the late Martin Mihm, MD, also at Massachusetts General; Thuy Phung, MD, a dermatologist at Texas Children's Hospital, Houston; and J. Stuart Nelson, MD, PhD, medical director of UC Irvine Beckman Laser Institute, Irvine, California, lent their support. More than 15 years later, the Vietnam Vascular Anomalies Center (VAC), the Ho Chi Minh City clinic that arose from this collaboration, has treated more than 10,000 children, at no cost to their families, with more than $1 million of laser technology donated by device manufacturers. Vietnam VAC has produced data useful both to clinicians in developed countries and to industry. And it has inspired other laser-based humanitarian startups in countries including Lebanon, Pakistan, and Armenia — and soon, Cambodia. At the Vietnam Vascular Anomalies Center (VAC), in Ho Chi Minh City, Vietnam, Thanh-Nga Tran, MD (center, examining the patient), with Rox Anderson, MD, to her right and clinic director, Minh Van Hoang, MD, PhD, behind them. Credit: Vietnam VAC. This last April, at The American Society for Laser Medicine and Surgery (ASLMS) 2025 Annual Meeting in Orlando, Florida, physicians involved in these international efforts brought their colleagues up to date on their projects. During the conference and in interviews afterward, they reflected on their accomplishments and on the many challenges that remain. A 15-Year Success in Vietnam Infantile hemangiomas are benign vascular tumors affecting about 4%-5% of newborns and are more common in girls. Though most will resolve spontaneously, they can be disfiguring; when they are especially aggressive, they can harm vision and interfere with breathing or feeding. 'The pulsed-dye laser allows for a nonscarring improvement or even removal,' Anderson said in an interview, but in 2009, Vietnam lacked any skin lasers at all. A device donated by Candela Corporation became the first to be imported and used in that country. On the day the clinic opened, 500 children were waiting with their parents. They had not only vascular lesions but also lymphatic malformations, congenital nevi, nevus of Ota, and 'myriad other disfiguring birthmarks that would otherwise go untreated in Vietnam,' Tran said at the meeting. And of course, many had scars from prior treatment with P-32. Tran, Anderson, and their colleagues quickly realized that the clinic would need different types of devices, including lasers to treat scars and pigmented lesions. Over time, more manufacturers, including Lumenis, Lutronic, and Cutera, donated devices. Teams of interventional radiologists and pediatric plastic surgeons from Texas Children's Hospital also traveled to Vietnam to treat patients with the most severe presentations. The VAC clinicians began hosting annual conferences in Vietnam to train local physicians there in laser medicine and dermatology. About 5 years into the program, Tran, Anderson, and their colleagues, including Minh Van Hoang, MD, PhD, the clinic's director, began publishing their findings. Their first reports described the harmful effects of P-32 treatment and a technique for combining laser treatments and epidermal grafting to improve scars in children treated with P-32. The same technique is currently being investigated in people with radiation dermatitis following breast cancer treatment. Between 20 and 40 children are seen on every treatment day at the VAC's Ho Chi Minh City clinic. Children with infantile hemangiomas may also receive propranolol, which the VAC team helped introduce in Vietnam. Though Vietnam VAC is a nonprofit organization registered in the US and supported by donations, its physicians may use lasers at designated times for paying patients, creating another source of revenue. Physicians at the high-volume clinic have contributed many case studies of rare presentations and other findings of value to specialists worldwide and manufacturers. 'There's a lot of talk at this conference about treating skin of color,' Tran told attendees at the ASLMS meeting. In Vietnam, she said, 'we treat skin of color every day with [a Q-switched Alexandrite laser]. We can manage congenital nevi, café au lait, and other conditions very safely.' Anderson noted at the meeting that the VAC's efforts also helped create a market in Vietnam for laser treatments, bolstered by a rapidly expanding local economy. Hundreds of clinicians in Vietnam and other parts of Asia have attended its annual training and CME sessions. This has changed local practice: The cancer center in Ho Chi Minh City, which had formerly administered P-32, dropped its use and acquired a pulsed-dye laser. At training conferences, 'we talk about how to treat kids, but we also talk about cosmetic stuff,' Anderson explained in an interview. 'The companies that donated the equipment are happy because they get to sell products. All boats rise when the tide comes in.' Vietnam VAC still faces challenges. 'Lasers break,' said Tran, now a researcher at the cutaneous biology research center at the Mass General Research Institute, Boston. 'We have to find help when they do.' Fundraising is another challenge. 'I've been hosting an annual benefit for the last 15 years — it's like doing a wedding every year. We don't raise a lot of money because, in the end, we're still small.' And despite many years of targeted outreach campaigns in the media and with doctors, the team has yet to fully eradicate the use of P-32 in Vietnam. Two remote clinics are rumored to be holdouts. 'Next year when I go, we're going to visit them,' Anderson said. 'We're going to put together a conference about phosphorus. You can't just get angry. You have to create a forum where people can really talk about it.' Lebanon: Tragic Blast Spurs a Laser Charity Energy-Based Medicine Specialist Zeina Tannous, MD, a dermatologist who also was trained with Anderson, was an assistant professor of dermatology at Harvard when, in 2011, she made the decision to return to her home country. She became the founding chair of dermatology at Lebanese American University in Beirut. Eight years later, Lebanon was hit by a dramatic financial crisis and currency devaluation that affected all sectors of society. Healthcare services were severely affected even among people with means, as people could not withdraw money from banks. Then, in August 2020, the unthinkable occurred. Thousands of tons of stored aluminum nitrate accidentally ignited at the port of Beirut, causing a massive explosion that killed hundreds and injured thousands. Tannous, who had just left the port zone at the time of the blast, returned immediately to aid in the emergency response, and spent days suturing victims. Blast survivors were left with severe, disfiguring scars. 'They were itchy, red, hypertrophic lesions resistant to treatment with injections of steroids,' Tannous said at the conference, 'probably because of the presence of the glass in them: a foreign body that was constantly inducing inflammation.' For 2 years, Tannous offered discounted laser treatments on her own and through aid organizations. But she did not own the type of laser needed to treat these glass scars, and the hospital that did 'needed to be paid,' she recalled. As in Vietnam, where the VAC doctors were able to get underway with a single donated device, one laser changed everything for Tannous: A fractional carbon dioxide laser provided pro bono by the Italian manufacturer Deka. That allowed Tannous to treat blast victims at no cost to them. Tannous's charity is not yet incorporated as a US-based nonprofit — 'we're working on that,' she said, but has nonetheless expanded, supported by her students and fellows and the recent donation of a vascular laser from Lutronic. The addition of that device has allowed Tannous to treat more vascular lesions in people who could not otherwise pay — including refugees from the war in Syria, many of whom struggle to meet their families' basic needs. 'These [vascular] birthmarks can bleed. They can obstruct vision. They can obstruct breathing. But in a time of war and a bad economy, people don't have the luxury of treating them, because the focus is on survival,' she said. Tannous, who continues to work closely with Anderson and others at Harvard, described in an interview how her personal mission has evolved far beyond her clinical research and practice. 'I would never refuse a patient if he or she doesn't have money,' she said, adding that she hopes that more energy-based medicine specialists will donate the monetary equivalent of even one treatment per year to efforts like hers and Tran's. 'Everybody has to do something for the people. Even if you're working for free. That's the message of medicine,' she said. Inspiring Others All over the world, free laser clinics are now emerging that follow a similar model with donated equipment and committed physicians, both local and visiting, who are generous with their time. Most of these international efforts share connections to Harvard and to Anderson, who has fiercely championed them and has not been shy about asking industry for help. 'The Pakistan clinic came about because one of my students was Pakistani and saw what we were doing,' said Anderson, who also works closely with a clinic in Armenia. In Cambodia, a physician is planning a clinic modeled after VAC, and another is being planned in Brazil. A newly formed umbrella group, called the Dream Beam Foundation, links all these global efforts and seeks to recruit more specialist volunteers. 'The clinics have different needs,' Anderson said, in terms of patient populations, predominant problems, and the technology and expertise available in each country. 'In Pakistan, for example, one of the most useful devices there is the fractional laser for scar revision.' But in each case, it is the human effort and dedication that will determine a clinic's success, he stressed. 'The lasers don't just stand alone. They're just tools.'
